Literature DB >> 2869348

Leishmania donovani: an opportunistic microbe associated with progressive disease in three immunocompromised patients.

R Badaró, E M Carvalho, H Rocha, A C Queiroz, T C Jones.   

Abstract

Three cases are described showing that Leishmania donovani can cause progressive disease in immunocompromised hosts. The first patient was receiving corticosteroid therapy for ulcerative colitis and the second corticosteroids and cyclophosphamide for proliferative glomerulonephritis; in the third patient, leishmaniasis occurred after a long episode of hepatosplenic schistosomiasis and salmonella bacteraemia which was treated with chloramphenicol. In two cases, the patients had moved away from areas of L donovani transmission many years before the progressive disease occurred, consistent with long-term survival of the organism in normal hosts. L donovani should be added to the growing list of opportunistic microbial infections.

Entities:  

Mesh:

Year:  1986        PMID: 2869348     DOI: 10.1016/s0140-6736(86)91725-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

1.  Visceral leishmaniasis complicating chronic hepatitis B treated with interferon.

Authors:  G Fattovich; G Giustina; F Adami
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

2.  One patient, two unusual conditions and three basic lessons.

Authors:  J M Gardner-Medwin; R J Powell
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

Review 3.  Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation.

Authors:  M T LaRocco; S J Burgert
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

4.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

Review 5.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

Review 6.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

7.  Persistence of elevated levels of galactosyl-alpha(1-3)galactose antibodies in sera from patients cured of visceral leishmaniasis.

Authors:  J L Avila; M Rojas; L García
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

8.  Visceral leishmaniasis associated with chronic granulomatous disease.

Authors:  M Mauri Pont; C Sánchez Rodríguez; F Bella Cueto; J Espaulella Panicot; J Homs Brubenga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

9.  Deficiency of lymph node-resident dendritic cells (DCs) and dysregulation of DC chemoattractants in a malnourished mouse model of Leishmania donovani infection.

Authors:  Marwa K Ibrahim; Jeffrey L Barnes; E Yaneth Osorio; Gregory M Anstead; Fabio Jimenez; John J Osterholzer; Bruno L Travi; Seema S Ahuja; A Clinton White; Peter C Melby
Journal:  Infect Immun       Date:  2014-05-12       Impact factor: 3.441

10.  Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient.

Authors:  H Albrecht; H J Stellbrink; G Gross; B Berg; U Helmchen; H Mensing
Journal:  Clin Investig       Date:  1994-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.